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Abstract 
Background: Postinfectious cough (PIC) significantly affects cough-related quality of life but still lacks effective 
treatments. This study aims to investigate the efficacy of QingfengGanke granule (QFGKG) in treating PIC induced by 
pathogenic wind invading lungs syndrome.
Methods: A multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted. A total of 180 
eligible participants were randomly (1:1:1) assigned to group A (QFGKG 6 g plus QFGKG-matched placebo 6 g), group 
B (QFGKG 12 g), and group C (QFGKG-matched placebo 12 g). All herbal medications were orally administered twice 
daily for 10 consecutive days. The primary outcome was time to cough resolution, and secondary outcomes included 
time to cough alleviation, mean changes in cough symptom score (CSS), visual analogue scale (VAS) score, cough-
specific quality of life questionnaire (CQLQ) score, and traditional Chinese medicine (TCM) syndrome score from 
baseline to Day 10, as well as adverse events.
Results: A total of 173 participants were included in the efficacy and safety analyses (group A, n = 57; group 
B, n = 57; group C, n = 59). The median time to cough resolution in groups A, B, and C was more than 10 days, 
8 days, and more than 10 days, respectively (P < 0.0001), and the median time to cough alleviation was 4, 4, and 
6 days, respectively (P < 0.0001). Compared with the placebo condition, groups A and B showed significantly 
greater improvements in CSS (P = 0.0005, P < 0.0001, respectively), VAS (P = 0.0002, P < 0.0001, respectively), CQLQ 
(P = 0.0258, P = 0.0003, respectively), and TCM syndrome (P = 0.0031, P < 0.0001, respectively). The time to cough 
resolution was faster in group B compared with group A (P = 0.0091). The adverse event profiles were comparable 
among the three groups.
Conclusion: QingfengGanke granule is efficacious in the treatment of PIC induced by pathogenic wind invading 
lungs syndrome.
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Background
Postinfectious cough (PIC), a cough lasting for at least 
3 weeks but not more than 8 weeks, is the most common 
cause of subacute cough, accounting for almost 50% of 
cases [1]. Respiratory viruses including influenza, Myco-
plasma pneumoniae, Chlamydia pneumoniae, Morax-
ella catarrhalis, and Bordetella pertussis have been 
implicated as causes of PIC [2–6]. PIC occurs in approx-
imately 10–40% of patients with upper respiratory tract 
infection (URTI) [2, 3]. During outbreaks of influenza or 
atypical infections, PIC may affect 25–50% of cases [2, 
4–6].
According to traditional Chinese medicine (TCM) 
theory, qi is managed mainly by the lungs, which control 
inspiration and expiration, and is particularly susceptible 
to pathogenic wind, leading to failure of the lungs to dis-
perse and descend. This results in dysregulation of dis-
persing and descending lung qi, manifested as coughing 
symptoms. PIC may be classified into the TCM disease 
category of “exogenous cough”; clinical practice and TCM 
syndrome research indicates that the “pathogenic wind 
(feng) invading lungs (fei)” syndrome is the most common 
type, which is mainly manifested as cough, throat itchi-
ness, throat dryness, chest tightness, and expectoration, 
along with pale red tongue, white or yellow tongue coat-
ing, and floating pulse [7].
Several pharmaceutical drugs have been used to relieve 
PIC, including inhaled ipratropium bromide, central act-
ing antitussive agents such as codeine and dextromethor-
phan, and inhaled or oral corticosteroids; however, drugs 
with optimal clinical efficacy and safety profiles are not 
yet available in Western medicine [8]. Evidence from 
randomized controlled trials (RCTs) of Chinese herbal 
medicine (CHM) treatments of PIC is not yet convincing 
because of small sample sizes and poor reporting quality 
[9].
QingfengGanke granule (QFGKG) consists of Mahuang 
(Ephedra sinica Stapf.), Qingfengteng (Sabia japonica 
Maxim.), Baibu (Stemona japonica (Bl.) Miq.), and Ziwan 
(Aster tataricus L. f.), with starch and sucrose excipi-
ents. The sources, pharmacological actions, and dosage 
of each ingredient are listed in Table  1. One preclinical 
pharmacodynamic experiment indicated the anti-inflam-
matory and immune modulatory properties of GFGKG 
(unpublished observation by Jia Jinliang), and prelimi-
nary clinical observational studies have shown its poten-
tial to relieve cough [10]. In addition, acute and chronic 
toxicological studies have revealed that GFGKG has no 
apparent toxic side effects (unpublished observation by 
Jia Jinliang).
This study aims to investigate the efficacy of QFGKG in 




Written informed consent was obtained from each sub-
ject prior to participation (Additional file  1). The study 
protocol was reviewed and approved by the Medical Eth-
ics Committee of West China Hospital at Sichuan Univer-
sity (Chengdu, China) (Additional files 2, 3, respectively). 
This study was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice ethi-
cal guidelines [11]. In addition, the trial was authorized 
by the China State Food and Drug Administration (No. 
2010L00279) and registered in the Chinese Clinical Trial 
Registry (ChiCTRTRC12002297). All herbs used in this 
trial are generally regarded as safe for use according to 
the China State Food and Drug Administration. The trial 
was reported in accordance with the Consolidated Stand-
ards of Reporting Trials (CONSORT) statement (Addi-
tional file 4) [12].
Table 1 QFGKG formula
QFGKG QingfengGanke granule, TCM traditional Chinese medicine.
Chinese Pinyin 
name
Botanical authority Family name Source Pharmacological actions in TCM Dosage/proportion 
(%) crude herb/1 g 
of QFGKG
Mahuang Ephedra sinica Stapf. Ephedraceae Dried her-
baceous 
stem
To release the exterior, disperse wind-cold; to stop 
wheezing due to obstruction of lung-qi; to reduce 
edema and promote urination especially due to 
obstruction from external wind-cold pathogen
375 mg/23.08
Qingfengteng Sabia japonica Maxim. Sabiaceae Dried rattan To expel wind-damp; to promote urination; to dredge 
collaterals or channels
500 mg/30.76




To moisten the lungs and relieve cough, excellent for 
chronic respiratory disorders and chronic cough; 
anti-parasitic
375 mg/23.08
Ziwan Aster tataricus L. f. Compositae Dried root 
and 
rhizome
To moisten the lungs and descend lung-qi; to stop 
acute or chronic cough
375 mg/23.08
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The randomization sequence was computer gener-
ated in blocks of five in a 1:1:1 ratio by an independ-
ent statistician using SAS statistical software (SAS 9.3, 
SAS Institute, USA). Allocation details were stored in 
two sealed envelopes. One set of envelopes was kept 
by QiHuang Drug Clinical Research Center (Beijing, 
China) and the other set was kept by the institutions at 
which the study was conducted to be opened in case of 
emergency. All researchers, participants, and statisti-
cians were masked to treatment allocation throughout 
the study.
Setting and participants
Potential participants diagnosed with PIC induced 
by pathogenic wind invading lungs syndrome, aged 
18–65  years old, were recruited by respiratory special-
ists with more than 5  years’ working experience from 
the outpatient departments of five participating cent-
ers across China: West China Hospital of Sichuan Uni-
versity, Tangdu Hospital of the Fourth Military Medical 
University, the Affiliated Hospital to Liaoning University 
of TCM, Nanjing First Hospital, and Baotou Central Hos-
pital. PIC was defined as a persistent cough triggered by 
URTI and lasting for 3–8  weeks [8, 13]. Using the Chi-
nese national criteria for clinical diagnosis and treatment 
evaluation of cough [14], pathogenic wind invading lungs 
syndrome was diagnosed in the presence of cough, throat 
itchiness, cough aggravated by pathogenic wind, and at 
least one of the other minor symptoms, along with pale 
red tongue, white or yellow tongue coating, and floating 
pulse. All participant inclusion and exclusion criteria are 
listed in Table 2.
Intervention
All participants were randomly allocated in a double-
blind manner to one of three parallel treatment groups: 
group A received QFGKG 6  g plus QFGKG-matched 
placebo 6  g, twice daily; group B took orally QFGKG 
12  g, twice daily; and group C took orally QFGKG-
matched placebo 12 g, twice daily. The scheduled treat-
ment duration was 10  days and the participants were 
followed up by scheduling visits to the clinic at baseline 
(Day 0), Day 5, and Day 10. All participants were treated 
in an equivalent fashion and instructed to avoid taking 
any other medication for the relief of cough. Compli-
ance was checked by examining a daily diary card and 
returned medication at the end of the study. Active and 
placebo granules that were indistinguishable in taste, 
color, appearance, and smell were issued in a sealed box 
and supplied by Baotou Chinese Traditional Medicine 
Co., Ltd. (China). All medications were dispensed by a 
specified drug administrator in a separate reception 
room.
Outcome measures
Cough symptom score (CSS)
The CSS is a validated tool to evaluate the frequency and 
severity of cough. Participants provided self-rated CSSs 
ranging from 0 to 3. Each evaluation day was divided into 
two intervals: daytime (from 8:00 am to 8:00  pm) and 
nighttime (from 8:00 pm to 8:00 am) [13]. CSS was evalu-
ated every day during the study.
Visual analogue scale (VAS)
The VAS is a 10 cm continuous horizontal line that meas-
ures the severity of cough. Participants were instructed to 
rate their cough severity from “no cough” to “extremely 
strong cough.” Scores ranged from 0 to 10. VAS score was 
assessed at baseline (Day 0), Day 5, and Day 10.
Cough‑specific quality of life questionnaire (CQLQ)
The CQLQ was designed specifically to evaluate decre-
ments in disease-targeted quality of life caused by cough 
and consists of 28 items in three domains (physical, 
Table 2 Inclusion and exclusion criteria
CSS cough symptom score, PIC postinfectious cough, QFGKG QingfengGanke 
granule, TCM traditional Chinese medicine.
Inclusion criteria
 Clinical diagnosis of PIC
 Pathogenic-wind invading lungs syndrome in TCM
 Baseline CSS of 2 or greater in the daytime and/or nighttime
 Cough lasting for at least 3 weeks but not more than 8 weeks
 Aged 18–65 years old
 Participant must voluntarily give written informed consent and report 
adverse events
Exclusion criteria
 Wheezing or rales on physical examination
 Bronchial provocation test positive
 Abnormal findings on plain chest radiograph
 Use of an angiotensin-converting-enzyme inhibitor within the past 
2 months
 Presenting with heartburn or regurgitation
 Symptoms or signs of upper airway cough syndrome
 Current smoker or recent ex-smoker (giving up smoking for less than 
3 months)
 Participant has severe primary disease of pulmonary, hepatic, renal, or 
hematological system, or other serious diseases affected the survival, 
such as cancer or AIDS
 ALT or AST >1.5 times of normal upper limit, abnormal serum creatine, 
abnormal serum Ig E, eosinophilia in the blood, white blood cell 
count <3× 109/L or >10 × 109/L/L, and/or neutrophil granulocyte 
>80%
 Pregnancy or lactating women, or women who have birth plan
 Allergic constitution or known to be allergic to any component in 
QFGKG
 Participants taking similar medicines in the last 1 month or having 
participated or participating in the other trials in last 3 months
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social, and psychological) [15]. A recent systematic 
review [16] showed that the CQLQ can provide valid 
and reliable outcomes for cough research. The minimum 
and maximum CQLQ scores were 28 and 112, respec-
tively, with lower scores indicating a better quality of life. 
CQLQ score was assessed at baseline and Day 10.
TCM syndrome score
Using the Chinese national criteria for clinical diagno-
sis and treatment evaluation of cough [14], the main and 
minor symptoms of the TCM syndrome were graded 
(cough: not at all = 0, mild = 2, moderate = 4, severe = 6; 
throat itchiness, throat dryness, and chest tightness: not at 
all = 0, mild = 1, moderate = 2, severe = 3; cough aggra-
vated by pathogenic wind and expectoration: yes = 0 and 
no = 2). The TCM syndrome score was the accumulated 
score of the main symptom score and all minor symptom 
scores. Additionally, tongue proper, tongue coating, and 
pulse were also assessed but not scored. TCM syndrome 
score was assessed at baseline and Day 10.
Safety evaluation
Safety evaluations included monitoring of adverse events 
(AEs), as well as clinical and laboratory findings. Partici-
pants were required to record any unexpected symptoms, 
signs, or feelings during the treatment period. In addi-
tion, routine tests of blood, urine and stool, hepatic and 
renal functions, and electrocardiogram were also per-
formed at baseline and again after the 10-day treatment 
to assess safety for each group.
The primary outcome was mean or median time to 
cough resolution, which was assessed as the length of 
time from the start of treatment until the first point at 
which cough resolved. Cough resolution was defined as 
both daytime and nighttime CSS decreasing to 0. The 
secondary outcomes included time to cough allevia-
tion, mean changes in CSS, VAS score, CQLQ score, and 
TCM syndrome score from baseline to Day 10, as well as 
adverse events. Cough alleviation was defined as a reduc-
tion in both daytime and nighttime CSS ≥ 1, lasting for 2 
consecutive days.
Sample size determination
No clinical trial data existed on the efficacy of QFGKG. 
Based on our experience and previous studies of other 
CHM formulae used to treat PIC [17–19], the cough 
resolution rates in the CHM and placebo groups were 
estimated to be 40 and 15%, respectively. The sample size 
for each group was calculated to be 53 according to the 
formula n = (Uα + Uβ)2 × 2P × (1 − P)/(P1 − P0)2 with a 
power of 90% or greater, assuming a significance level of 
0.05. To allow for a dropout rate of approximately 10%, 
180 PIC participants were needed for this study.
Statistical analysis
All the efficacy and safety analyses were performed using 
the intent-to-treat population. All data were documented 
by two independent individuals and the data files were 
secured. Statistical analyses were conducted using statistical 
software (SAS 9.3, SAS Institute, USA). Normally distrib-
uted quantitative data were described as mean  ±  stand-
ard deviation and analyzed using analysis of variance. 
Quantitative data that were not normally distributed were 
expressed as median and analyzed by the Wilcoxon rank-
sum test. Qualitative data were presented as frequency and 
percentage and analyzed using Chi square (χ2) or Fisher’s 
exact test. The primary outcome was analyzed using the 
survival method. Kaplan–Meier curves were constructed 
and differences between curves were tested by the log-rank 
method. The secondary outcomes were analyzed using 
analysis of covariance with a Bonferroni correction, or the 




A total of 180 eligible participants were enrolled from 
five tertiary hospitals across China between April 2011 
and March 2012, and randomly assigned 1:1:1 to receive 
low-dose QFGKG (group A, n = 60), high-dose QFGKG 
(group B, n = 60), or placebo (group C, n = 60). Of these, 
seven participants were withdrawn from the study for sev-
eral reasons, including protocol violation (group A, n = 1; 
group B, n = 1), lost to follow-up (group A, n = 1; group 
B, n = 1; group C, n = 1), and refusal to continue (group 
A, n = 1; group B, n = 1). Overall, 173 participants were 
included in the efficacy and safety analyses (Figure  1). 
Compliance measured by daily diary card and returned 
medication was 96%. Use of concomitant medications 
including herbal and complementary medicines did not 
differ across the three groups (P = 0.9378). No differences 
in demographic or clinical characteristics were observed 
among the three groups at baseline (Table 3).
Time to cough resolution
The median time to cough resolution in groups A, B, and 
C was more than 10 days, 8 days, and more than 10 days, 
respectively. A significant therapeutic effect was noted in 
both QFGKG groups compared with the placebo condi-
tion (group A, P < 0.0001; group B, P < 0.0001), and the 
time to cough resolution was faster in group B compared 
with group A (P = 0.0091) (Figure 2).
Time to cough alleviation
The median time to cough alleviation in groups A, B, 
and C was 4, 4, and 6  days, respectively. The between-
group differences were statistically significant (group A, 
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P = 0.0003; group B, P < 0.0001), except for the difference 
between group A and group B (P = 0.1843) (Figure 3).
CSS
Significant improvements in CSS (both daytime and 
nighttime) were observed from baseline to Day 10 in 
all three groups (group A, 3.84  ±  0.80 to 1.14  ±  1.11; 
group B, 3.79 ± 0.77 to 0.79 ± 1.19; group C, 3.86 ± 0.84 
to 2.22  ±  1.54). Both QFGKG groups showed signifi-
cantly greater improvements compared with the placebo 
[group A, −1.07, 95% confidence interval (CI) −1.55 
to −0.6, P  =  0.0005; group B, −1.41, 95% CI −1.89 to 
−0.94, P  <  0.0001]. Group B showed a greater, though 
non-significant, improvement compared with group A 
(P  =  0.5406). Similar improvements were observed in 
both daytime and nighttime CSS (Table 4).
VAS
Significant changes from baseline in VAS score were found 
in all three groups (group A, 6.04 ± 1.44 to 1.81 ± 1.87; 
group B, 5.90 ± 1.23 to 1.12 ± 1.70; group C, 5.96 ± 1.33 
to 3.41 ± 2.11). Both QFGKG groups showed significantly 
greater improvements compared with the placebo condi-
tion (group A, −1.63, 95% CI −2.31 to −0.95, P = 0.0002; 
Figure 1 Flow chart of participants through study.
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group B, −2.26, 95% CI −2.95 to −1.58, P < 0.0001). Group 
B showed a greater, though non-significant, improvement 
compared with group A (P = 0.4200) (Table 4).
CQLQ
Significant improvements in the total CQLQ scores 
were observed from baseline to Day 10 in all three 
groups (group A, 64.51  ±  9.58 to 48.27  ±  14.30; group 
B, 64.95 ± 7.31 to 44.82 ± 14.10; group C, 64.78 ± 6.46 
to 54.89 ± 10.59). Compared with the placebo condition, 
participants in either QFGKG group had a better quality of 
life (group A, −6.17, 95% CI −10.4 to −1.88, P = 0.0258; 
group B, −9.65, 95% CI −13.9 to −5.4, P = 0.0003), but 
there was no significant difference between the high- and 
low-dose QFGKG groups (P = 0.5720) (Table 4).
TCM syndrome score
Again, improvements in the total TCM syndrome score 
were observed from baseline to Day 10 in all three 
groups (group A, 12.02 ±  2.60 to 3.49 ±  3.51; group B, 
11.46  ±  1.97 to 2.00  ±  3.00; group C, 11.97  ±  2.17 to 
6.17 ±  4.00). Both QFGKG groups showed significantly 
greater improvements compared with the placebo condi-
tion (group A, −2.7, 95% CI −3.97 to −1.42, P = 0.0031; 
Table 3 Demographic and clinical characteristics at baseline
Values are reported as mean ± SD or as frequency (%).
CQLQ cough-specific quality of life questionnaire, CSS cough symptom score, PIC postinfectious cough, TCM traditional Chinese medicine, VAS visual analogue scale.
* P values obtained via variance analysis for continuous variables, or Chi square tests for categorical variables.
Characteristics Group A (n = 57) Group B (n = 57) Group C (n = 59) P values*
Age (years) 44.37 ± 12.38 43.07 ± 12.67 44.07 ± 12.65 0.8663
Gender (female/%) 35 (61.40) 35 (61.40) 31 (52.54) 0.5336
Body weight (kg) 62.41 ± 9.91 62.45 ± 10.76 63.44 ± 10.87 0.6680
Height (cm) 164.26 ± 7.89 163.22 ± 7.99 164.47 ± 8.59 0.6097
Former smoker (n (%)) 10 (17.54) 5 (8.77) 5 (8.47) 0.2255
Cough duration (days) 33.00 ± 10.32 29.96 ± 7.09 30.80 ± 8.96 0.3685
Previous diagnosis of PIC (n (%)) 9 (15.79) 8 (14.04) 10 (16.95) 0.9696
VAS score 6.04 ± 1.44 5.90 ± 1.23 5.96 ± 1.33 0.8341
CSS 3.84 ± 0.80 3.79 ± 0.77 3.86 ± 0.84 0.9648
Daytime CSS 2.12 ± 0.38 2.02 ± 0.35 2.14 ± 0.43 0.2084
Nighttime CSS 1.72 ± 0.65 1.77 ± 0.68 1.73 ± 0.69 0.7752
CQLQ score 64.51 ± 9.58 64.95 ± 7.31 64.78 ± 6.46 0.9068
TCM syndrome score 12.02 ± 2.60 11.46 ± 1.97 11.97 ± 2.17 0.1492
Figure 2 Time to cough resolution in participants with PIC.
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group B, −4.05, 95% CI −5.33 to −2.76, P < 0.0001), but 
the difference between the two QFGKG groups did not 
reach significance (P = 0.3692) (Table 4).
Safety
There were neither serious AEs nor participant with-
drawal because of AEs during the study. Participants 
taking QFGKG regardless of dosage reported more AEs 
than those in the placebo group (7.02 vs. 7.02 vs. 1.69%; 
P = 0.3313). In group A, AEs were reported in four par-
ticipants. One participant reported dizziness and a rough 
tongue (at Day 1), which were resolved within 10  days. 
One participant complained of arm itchiness (at Day 1), 
which was resolved within 4  days. Another two repro-
ductive-aged women showed a slightly elevated level of 
white blood cells in routine urine tests after treatment 
without any symptoms of urinary tract infection at Day 7 
and 10, respectively; the events were resolved after drink-
ing more water. In group B, four participants reported 
AEs. One male participant had mild hepatic dysfunction 
with baseline alanine aminotransferase 48  U/L increas-
ing to 60  U/L after treatment, but dropping to normal 
when measured again 3 days later without any interven-
tion. One participant developed URTI with an elevated 
level of white blood cells (7.31 ×  109/L pretreatment to 
11.17  ×  109/L posttreatment); the event was resolved 
7  days later after the administration of antibiotics. Two 
reproductive-aged women experienced an elevated level 
of white blood cells in routine urine tests after treatment 
without any discomfort at Day 6 and 11, respectively; the 
events were resolved after drinking more water. In group 
C, one participant complained of a mild episode of diz-
ziness. All the reported AEs were generally considered 
mild in severity, manageable, and reversible.
Figure 3 Time to cough alleviation in participants with PIC.
Table 4 Analyses of CSS, VAS, CQLQ scores, and TCM syndrome score
Values are reported as mean ± SD.
CQLQ cough-specific quality of life questionnaire, CSS cough symptom score, TCM traditional Chinese medicine, VAS visual analogue scale.
* P < 0.01 for group A/group B vs. group C.
Outcome variables Change from baseline to Day 10
Group A (n = 57) Group B (n = 57) Group C (n = 59) P values*
CSS −2.70 ± 1.30* −3.00 ± 1.28* −1.64 ± 1.64 <0.0001
Daytime CSS −1.39 ± 0.70* −1.58 ± 0.71* −0.78 ± 0.87 <0.0001
Nighttime CSS −1.32 ± 0.83* −1.42 ± 0.75* −0.86 ± 0.96 <0.0001
VAS −4.24 ± 2.10* −4.78 ± 2.01* −2.55 ± 2.28 <0.0001
CQLQ score −16.09 ± 14.14* −20.12 ± 14.61* −9.75 ± 11.99 <0.0001
TCM syndrome score −8.53 ± 3.74* −9.46 ± 3.00* −5.80 ± 4.51 <0.0001
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Discussion
To our knowledge, this is the first randomized, double-
blind, placebo-controlled clinical trial of CHM in the 
treatment of PIC induced by pathogenic wind invad-
ing lungs syndrome. QFGKG could shorten the dura-
tion of cough, decrease cough severity and frequency, 
and improve cough-specific quality of life. In addition, 
this study found QFGKG to be safe and well tolerated. 
High-dose QFGKG appeared to be superior to low-dose 
QFGKG in shortening the duration of cough.
QingfengGanke granule improved cough and cough-
related quality of life in both QFGKG groups. Similarly, 
significant improvements were found in the placebo 
group, most likely because of the self-limiting nature of 
PIC. In addition to natural recovery, the placebo effects 
might encompass several other components: regression 
of cough response toward the mean, true placebo effect, 
voluntary control, and effects related to expectancy and 
meaning of the treatment [20].
Although the pathogenesis of PIC remains unknown, 
airway inflammation, epithelial disruption, and cough 
hyper-responsiveness are involved [8]. The resurgence 
of pertussis or whooping cough has prompted wide pub-
lic and clinical concerns over the last 20  years [21–23]. 
There is an increasing recognition of the presence of Bor-
detella pertussis infection in PIC, although URTI is the 
most common cause. Approximately 12–50% of cases 
with cough duration of 2 weeks or more show evidence of 
recent B. pertussis infection despite aggressive vaccina-
tion [24]. Although some medications are available, there 
is no proven effective therapy for patients with prolonged 
cough attributed to pertussis [25]. A recent double-blind, 
placebo-controlled RCT [26] indicated that nebulized 
ipratropium bromide in combination with salbutamol 
could reduce PIC. Another recent placebo-controlled 
RCT [27] showed that montelukast, a cysteinyl leukot-
riene type 1 receptor antagonist, was not an effective 
treatment for PIC. Whether there is a potential therapeu-
tic effect of QFGKG on pertussis-related cough deserves 
further study.
In terms of safety, no deaths or serious AEs were 
reported; all AEs reported were of mild severity. Three 
AEs were categorized as possibly or probably related to 
the study medication: dizziness, rough tongue, and arm 
itchiness. An elevated level of white blood cells in rou-
tine urine tests, which occurred in four female partici-
pants in the QFGKG groups, was considered unrelated 
to the study medication and probably associated with an 
increased risk of urinary tract infection in young women 
of reproductive age. Some mild abnormalities observed 
in laboratory safety evaluations in the high-dose QFGKG 
group were judged as unrelated to the study medica-
tion. However, Mahuang in QFGKG may have some 
side effects, such as increased blood pressure, cardiac 
arrhythmia, excitability, insomnia, nausea, poor appetite, 
or convulsions [28].
Some potential limitations of the present study should 
be considered. First, cough frequency was subjectively 
assessed in this study using a cough diary. There is increas-
ing evidence that acoustic cough-monitoring devices can 
be valid and reliable instruments with which to assess 
cough frequency. However, the absence of good responsive-
ness and inconsistency with other instruments has limited 
their wide use in cough research [16, 29]. Second, our study 
protocol specifically excluded elderly people and those with 
mild cough, limiting the generalizability of the study find-
ings in real-life clinical practice. Third, there was no follow-
up after treatment, so the effect of QFGKG on relapse rate 
after treatment was unknown. Moreover, the accuracy of 
determining the time to cough alleviation might have been 
impaired, as 2 days was needed to define cough alleviation.
Conclusion
QingfengGanke granule is efficacious in the treatment 
of PIC induced by pathogenic wind invading lungs 
syndrome.
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